28-Mar-2024
Catalyst Watch: Tesla deliveries, Disney board vote, DJT drama and Fortinet event
Seeking Alpha News (Thu, 28-Mar 3:00 PM ET)
Business Wire (Wed, 27-Mar 9:00 AM ET)
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
Business Wire (Mon, 18-Mar 9:00 AM ET)
Globe Newswire (Mon, 26-Feb 9:00 PM ET)
Icahn Enterprises L.P. Announces Management & Financial Update
PRNewswire (Wed, 21-Feb 9:00 AM ET)
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
PRNewswire (Thu, 8-Feb 4:05 PM ET)
Business Wire (Thu, 1-Feb 9:00 AM ET)
Business Wire (Tue, 30-Jan 9:00 AM ET)
PRNewswire (Mon, 15-Jan 7:00 AM ET)
BeniComp to Offer GRAIL's Multi-Cancer Early Detection Test for Employee Health Screening
Business Wire (Thu, 11-Jan 9:00 AM ET)
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Illumina trades on the NASDAQ stock market under the symbol ILMN.
As of March 28, 2024, ILMN stock price declined to $137.32 with 854,816 million shares trading.
ILMN has a beta of 1.73, meaning it tends to be more sensitive to market movements. ILMN has a correlation of 0.21 to the broad based SPY ETF.
ILMN has a market cap of $21.81 billion. This is considered a Large Cap stock.
Last quarter Illumina reported $1 billion in Revenue and $.14 earnings per share. This beat revenue expectation by $32 million and exceeded earnings estimates by $.12.
In the last 3 years, ILMN stock traded as high as $526.00 and as low as $89.00.
The top ETF exchange traded funds that ILMN belongs to (by Net Assets): VTI, VOO, VO, QQQ, SPY.
ILMN has underperformed the market in the last year with a return of -37.0%, while the SPY ETF gained +33.6%. In the last 3 month period, ILMN fell short of the market, returning -3.7%, while SPY returned +10.1%. However, in the most recent 2 weeks ILMN has outperformed the stock market by returning +3.4%, while SPY returned +1.7%.
ILMN support price is $134.90 and resistance is $142.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ILMN stock will trade within this expected range on the day.